Date: 2012-01-18
Type of information:
phase: 1
Announcement: completion
Company: InflaRx (Germany)
Product: IFX-1 (monoclonal antibody inhibiting complement driven inflammation)
Action mechanism:
Disease:
Therapeutic area:
Country:
Trial details:
Latest
news: InflaRx has announced the successful completion of its clinical phase I study investigating its lead drug candidate IFX-1, a new first in class monoclonal antibody inhibiting complement driven inflammation.
The trial reached its endpoints, demonstrating that IFX-1 is safe and well tolerated while displaying desirable PK and PD parameters.
IFX-1 was designed primarily to control the inflammatory response in acute diseases, lead by the sepsis indication.The company is currently extending development of this technology into other inflammatory indications.
